- Conditions
- AML, Adult
- Interventions
- BST-236, venetoclax
- Drug
- Lead sponsor
- BioSight Ltd.
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Houston, Texas • Charlottesville, Virginia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 1,327
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Gaucher Disease, Type 1 Gaucher Disease, Gaucher Disease, Type 1
- Interventions
- afegostat tartrate
- Drug
- Lead sponsor
- Amicus Therapeutics
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 7
- States / cities
- Beverly Hills, California • Coral Springs, Florida • Decatur, Georgia + 4 more
- Conditions
- CLL / SLL, CLL (Chronic Lymphocytic Leukemia), SLL (Small Lymphocytic Lymphoma), Marginal Zone Lymphoma(MZL), Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia
- Interventions
- Lonitoclax (ZE50-0134)
- Drug
- Lead sponsor
- Lomond Therapeutics Holdings, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 5
- States / cities
- Louisville, Kentucky • Chapel Hill, North Carolina • Cincinnati, Ohio + 2 more
- Conditions
- Parkinson Disease
- Interventions
- Placebo, PF-06649751 low dose (1 mg QD), PF-06649751 middle dose 1 (3 mg QD), PF-06649751 middle dose 2 (7 mg QD), PF-06649751 high dose (15 mg QD)
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 33
- States / cities
- Phoenix, Arizona • Arcadia, California • Loma Linda, California + 26 more
- Conditions
- AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hepatocellular Carcinoma, HIV Infection, Kaposi Sarcoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma, Recurrent Malignant Neoplasm, Refractory Classic Hodgkin Lymphoma, Refractory Malignant Neoplasm, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Unresectable Melanoma
- Interventions
- Antiretroviral Therapy, Biopsy, Biospecimen Collection, Computed Tomography, Pembrolizumab, Positron Emission Tomography
- Drug · Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 6 more
- Conditions
- Advanced Ovarian Cancer, Triple Negative Breast Cancer
- Interventions
- Atezolizumab, RO6870810
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Oklahoma City, Oklahoma • Nashville, Tennessee
- Conditions
- Relapsed Childhood ALL, Relapsed Childhood Lymphoblastic Lymphoma
- Interventions
- Venetoclax, Navitoclax
- Drug
- Lead sponsor
- Kathleen Ludwig
- Other
- Eligibility
- 4 Years and older
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Idiopathic Hypersomnia
- Interventions
- Serdexmethylphenidate, Placebo
- Drug · Other
- Lead sponsor
- Zevra Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Daphne, Alabama • Guntersville, Alabama + 34 more
- Conditions
- CLL/SLL, Waldenstrom Macroglobulinemia, Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Hairy Cell Leukemia
- Interventions
- LP-168
- Drug
- Lead sponsor
- Newave Pharmaceutical Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 4
- States / cities
- Durham, North Carolina • Cincinnati, Ohio • Columbus, Ohio + 1 more
- Conditions
- Bipolar Disorder
- Interventions
- Aripiprazole, placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 296 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 53
- States / cities
- Scottsdale, Arizona • Little Rock, Arkansas • National City, California + 50 more
- Conditions
- Brain Metastases
- Interventions
- encorafenib, binimetinib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 11
- States / cities
- Los Angeles, California • San Francisco, California • Santa Monica, California + 3 more
- Conditions
- Hypogonadism
- Interventions
- Testosterone undecanoate, Testosterone enanthate
- Drug
- Lead sponsor
- Clarus Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 2
- States / cities
- Los Angeles, California • San Antonio, Texas
- Conditions
- Healthy
- Interventions
- PF-07258669, Itraconazole
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- Hollywood, Florida
- Conditions
- Psoriasis Vulgaris
- Interventions
- KD025
- Drug
- Lead sponsor
- Kadmon Corporation, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 9
- States / cities
- Glendale, Arizona • Santa Ana, California • Lake Charles, Louisiana + 6 more
- Conditions
- Solid Tumors
- Interventions
- INCB0123667, Palbociclib, Bevacizumab, Olaparib, Paclitaxel, Ribociclib, Fulvestrant
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 291 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 18
- States / cities
- Duarte, California • Irvine, California • Los Angeles, California + 13 more
- Conditions
- Hypogonadism
- Interventions
- Androderm®
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years to 80 Years · Male only
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 37 more
- Conditions
- Anemia, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis
- Interventions
- INCB000928, ruxolitinib
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 13
- States / cities
- Duarte, California • Irvine, California • Los Angeles, California + 9 more
- Conditions
- Smoking Cessation
- Interventions
- CP-526,555 (varenicline)
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 625 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2002
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Farmington, Connecticut • Minneapolis, Minnesota + 4 more
- Conditions
- Gout
- Interventions
- Allopurinol, Dotinurad
- Drug
- Lead sponsor
- Crystalys Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 89
- States / cities
- Birmingham, Alabama • Foley, Alabama • Gilbert, Arizona + 81 more
- Conditions
- Colorectal Neoplasms
- Interventions
- Vicriviroc, Pembrolizumab
- Drug · Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • Encinitas, California • Fresno, California + 3 more
- Conditions
- Trauma, Surgery, Deep Vein Thrombosis (DVT), Thromboembolic Events
- Interventions
- Enoxaparin Sodium Injection 30 mg BID, Enoxaparin Sodium Injection 40 mg QD
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 15 Years to 100 Years
- Enrollment
- 606 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2025
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis
- Interventions
- CYT387
- Drug
- Lead sponsor
- Sierra Oncology LLC - a GSK company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 166 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 3
- States / cities
- Stanford, California • Boston, Massachusetts • Rochester, Minnesota
- Conditions
- Acute Pain
- Interventions
- VX-150, Placebo
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Anaheim, California • Pasadena, California + 3 more
- Conditions
- Non-Hodgkin's Lymphoma, Leukemia, Multiple Myeloma, Acute Myeloid Leukemia, Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome
- Interventions
- Thymoglobulin, Total-Body Irradiation, Allogeneic PBSCT or BMT, Tacrolimus, Mycophenolate Mofetil
- Biological · Radiation · Procedure + 1 more
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 40 Years to 70 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2017
- U.S. locations
- 1
- States / cities
- Richmond, Virginia